CA102N is an innovative investigational anticancer drug designed for the treatment of solid tumors, including colorectal cancer.  CA102N is a carrier-mediated drug delivery product with hyaluronic acid (HA) conjugated to Nimuselide. The Hyaluronic Acid – Drug Conjugation (HADC) platform is specifically engineered to target the CD44 receptor overexpressed in solid tumors. HSHC has secured the patent protection of its HADC platform.

HSHC(4194.TW) submitted an Investigational New Drug (IND) application to the US FDA for CA102N to initiate a phase II clinical trial in subjects with metastatic colorectal cancer (mCRC) who failed the standard treatment.